ERT and Foundry3 Partner to Deliver Best-in-class Patient Support Programs

Share Article

Insight into patient behaviors and scalable digital health services combine to improve clinical outcomes


“Together with Foundry3, we are able to deliver tailored support programs that patients value because they’re built with patient insight and will truly improve people’s lives,” said Tim Davis, VP, Digital Patient, ERT.

ERT, a global data and technology company dedicated to improving health outcomes through innovative drug development and patient support solutions, and Foundry3, a creative, science and innovation agency, today announced a partnership to create tailored digital health programs that improve clinical outcomes by providing support to patients throughout their healthcare journeys.

The partnership brings together the expertise of two organizations with distinct capabilities in driving digital health program success. Foundry3 adds its unique approach to uncovering the challenges and motivators that impact patient behaviors to ERT’s global expertise in delivering regulatory-compliant drug development and patient support solutions for the pharmaceutical industry. Together they will deliver rich, adaptive digital health programs ─ based on substantiated patient needs ─ to help patients better manage their conditions, ultimately improving health outcomes.

“At Foundry3 we listen to the voice of the patient to design successful digital health support initiatives based on positive behavior change, value to the patient and clinical relevance,” said Alex Butler, Co-founder of Foundry3. “By partnering with ERT, we leverage their 50 years of scientific, clinical and technology expertise to provide the global scale, structure and governance needed to meet the pharmaceutical industry’s growing demand for more effective global patient support programs.”

“In order to optimize treatment effect and improve quality of life, support programs must be built around patients’ needs, a critical factor that’s been missing from some of the industry’s digital health initiatives,” said Tim Davis, Vice President, Digital Patient, ERT. “Together with Foundry3, we are able to deliver tailored support programs that patients value because they’re built with patient insight and will truly improve people’s lives.”

For more information visit


About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to or follow us on LinkedIn and Twitter.

About Foundry3
Foundry3 is a science, creativity and innovation company working to build the future of healthcare in partnership and collaboration with our clients. Most importantly we exist to solve problems, enabling companies to better support their products in fast moving world where the opportunities to improve people’s lives through the combination of science, creativity and technological innovation have never been more exciting and were almost unimaginable even a decade ago.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christine Tobin
+1 4127194568
Email >